Precision medicine in Type 2 Diabetes: Targeting SGLT2-inhibitor Treatment For Kidney Protection - Jansz, Thijs T; Young, Katherine G; Hopkins, Rhian; McGovern, Andrew P; Shields, Beverley M; Hattersley, Andrew T; Jones, Angus G; Pearson, Ewan R; Oram, Richard A; Dennis, John M; MASTERMIND Consortium (medRxiv, 2024)
Background Current guidelines recommend sodium-glucose cotransporter-2 inhibitors (SGLT2i) for kidney protection to a broad range of people with type 2 diabetes (T2D), but many were not represented in key kidney outcome trials and have unclear benefit. We aimed to identify which of these people are likely to benefit.Methods We studied 134,420 adults with T2D, estimated glomerular filtration rate (eGFR) >=20mL/min/1.73m2, no cardiovascular disease or heart failure, starting SGLT2i (34%) or dipeptidyl peptidase-4 inhibitors/sulfonylureas (DPP4i/SU, 66%) in UK primary care (Clinical Practice Research Datalink, 2013-2020). We first validated the hazard ratio (HR) for kidney disease progression (>=50% eGFR decline, end-stage kidney disease, or kidney-related death) from SGLT2i trial meta-analysis. We then integrated this with established prediction models (CKD Prognosis Consortium risk score for 3-year risk of kidney disease progression) to estimate SGLT2i benefit (absolute risk reductions [ARR]) and validated the accuracy of these estimates.Findings The multivariable-adjusted SGLT2i HR for kidney disease progression was 0.60 (95%CI 0.52-0.70) compared to DPP4i/SU, consistent with SGLT2i trial meta-analysis and across eGFR/albuminuria subgroups (interaction p=0.36). Predicted SGLT2i benefit was consistent with observed and was substantial (ARR >=0.85%) in two subgroups: 1) eGFR <60mL/min/1.73m2 or albuminuria >=30mg/mmol; 2) eGFR >=60mL/min/1.73m2, albuminuria 3-30mg/mmol, and predicted ARR >=80th percentile. Benefit was limited (ARR <=0.38%) in all others with eGFR >=60mL/min/1.73m2. This latter group with limited benefit comprises 46% of those recommended SGLT2i for kidney protection.Interpretation SGLT2-inhibitor treatment could be targeted to those with substantial predicted kidney protection benefit. Guidelines should consider stratifying treatment recommendations based on predicted benefit.Competing Interest StatementAGJ declares research funding to his university from the UK Medical Research Council, Diabetes UK, JDRF, and the European Foundation for the Study of Diabetes. ERP has received honoraria for speaking from Lilly, Novo Nordisk and Illumina. No industry representatives were involved in the writing of the manuscript or analysis of data. For all authors these are outside the submitted work; there are no other relationships or activities that might bias, or be perceived to bias, their work. Funding StatementThis research was funded by the Medical Research Council (UK) (MR/N00633X/1), and supported by EFSD/Novo Nordisk. JMD is supported by a Wellcome Trust Early Career award (227070/Z/23/Z). ATH and BMS are supported by the NIHR Exeter Clinical Research Facility; the views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. AGJ was supported by an NIHR Clinician Scientist fellowship (CS-2015-15-018).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval for CPRD data access and the study protocol was granted by the CPRD Independent Scientific Advisory Committee (eRAP protocol number: 22_002000).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesCPRD data are available by application to the CPRD Independent Scientific Advisory Committee. All R code to reproduce the analyses in this paper is available at https://github.com/Exeter-Diabetes/CPRD-Thijs-SGLT2-KF-scripts https://github.com/Exeter-Diabetes/CPRD-Thijs-SGLT2-KF-scripts https://github.com/Exeter-Diabetes/CPRD-Codelists https://github.com/Exeter-Diabetes/CPRD-Cohort-scripts